BPH Corporate Limited BPH Corporate Limited [ASX: BPH]
Overview
BPH Corporate (previously BioPharmica Limited) was formed in 2004 and is a listed company on the Australian Securities Exchange under code BPH. The company is commercialising a portfolio of Australian biomedical technologies emerging from research by leading Universities, Medical Institutes and Hospitals across Australia. Targeting large global markets BPH provides product development and commercial direction, whilst the institutional partner provides the majority of the infrastructure and research expertise.
Technologies on the way to commercialisation include: Diagnostic Array Systems, BacTrak a faster and more effective method of detecting infectious disease; Cortical Dynamics Brain Anaesthesia Response (BAR) Monitor - a device that measures a patient’s brain electrical activity (EEG) to indicate the response to drugs administered during surgery; HLS5 Tumour Suppress Gene a molecular marker for early and accurate cancer detection; and microtubule drugs that target the tumour vasculature.
Molecular Discovery Systems (MDSystems) is a 19.5% owned subsidiary of BPH that was launched in 2006 for drug discovery and the validation of biomarkers for disease, therapy and diagnostics. The company utilizes the InCell Analyser 1000 for high throughout imaging and analysis, providing services for researchers worldwide.
BPH has an interest in a SERS Nanoprobe an optical fibre to be used in biosensors for diagnostic testing and drug development.
BPH Corporate also has investment with Advent Energy Limited which is an unlisted oil and gas exploration company. Advent holds a strong portfolio of exploration and near-term production assets throughout Australia. Advent’s cornerstone project lies off the coast of NSW in Petroleum Exploration Permit 11 (PEP11), and has been estimated to comprise up to 16.3 Tcf (P10 or ‘high’ level) prospective recoverable gas resources.
Number of employees: 4
Main business focus/
Listing by sector:
- Drug Discovery & Development
- Medical Devices
- Diagnostics
- Infectious Diseases
- Biodiscovery
Competitive Advantages
BPH Corporate Limited partners with academic institutions on projects that have excellent scientific merit, strong IP position and commercial potential.
Research is carried out by the acknowledged experts in the field while BPH provides the commercial direction and focus.
BPH has a balanced management system combining corporate and scientific expertise.
The company head office is based in Perth, Western Australia giving it an ideal position for interactions with South East Asia.
BPH facilitates the tech-transfer process from academia to the pharma / biotech industry and provides potential partners / licensees with attractive opportunities.
Technology/IP
BPH has a number of patents lodged in each area of their current project portfolio.
Corporate Alliances/Partnerships
Western Australian Institute for Medical Research (WAIMR) which combines the Royal Perth Hospital, Sir Charles Gairdner Hospital, Fremantle Hospital and University of Western Australia (UWA). BPH also has aliances with Royal Melbourne Institute of Technology University (RMIT) and Swinburne University of Technology (SUT).
Partnering Opportunities
BPH is seeking companies and institutions interested in co-development or collaboration in the following areas:
- An exceptional opportunity exists for a drug development company to co-develop a drug candidate validation program in the field of anti-Microtubule cancer therapeutics.
An exciting opportunity exists for a diagnostic company to license the BacTrak technology in the field of respiratory infection diagnosis. The BacTrak System is a diagnosis test for the detection of multiple bacteria in single sputum sample (e.g. diagnosis of pneumonia). The System is a PCR/microarray based system which is a faster system compared to conventional microbiological systems.
The use of brain anesthesia response (BAR) index monitoring capability in animals and man.
Contract services are also available utilising the InCell Analyser 1000 which combines high resolution imaging and high content analysis to provide a technology that rapidly detects and quantifies components of the cell much faster than conventional methods. Image capture and analyse is conducted by trained personnel to provide results.
Partnering Needs
BPH Corporate is seeking companies and insitutions interested in co-development, collaboration and/or licensing.
Contact Details
| Contact person | Mr David Breeze |
|---|---|
| Job Title | Chairman |
| Address | PO Box 317 |
| City/Suburb | North Perth |
| State | Western Australia |
| david@bphcorporate.com.au | |
| Phone | +61 8 9328 8366 |
| Fax | +61 8 9328 8733 |
| Website | http://www.bphcorporate.com.au |
